Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microlyvaq in advanced non-small cell lung cancer
NCT07285434Phase 1Enrolling by invitation
- Sponsor
- Biogenea Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Microlyvaq in non-small cell lung cancer (NSCLC), sponsored by Biogenea Pharmaceuticals. Primary endpoints: Overall Survival at 36 months and Objective Response Rate at 14 weeks. Started Feb 2026; status: enrolling by invitation.
02
Drugs
Microlyvaq
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07285434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285434.